title: [Expression of PIGF and Its receptor Flt-1 in Patients with Multiple Myeloma and their Correlation with Chemotherapeutic Efficacy].
abstract: OBJECTIVE
  To investigate the expression of PIGF and its receptor Flt-1 in patients with multiple myeloma, and to analyze their correlation with the efficacy of thalidomide-based chemotherapy so as to provide further theoretical basis for individualized treatment.
  
  
  METHODS
  A total of 35 patients diagnosed as multiple myeloma from June 2012 to March 2013 in our hospital and 15 non-tumor patients as controls were enrolled in this study. MM patients were treated with thalidomide-based chemotherapy for 3 months, and then were grouped according to the curative effecacy. The expression levels of PIGF and Flt-1 were detected in bone marrow of control and MM patient group by RT-PCR and Western blot before and after chemotherapy, their correlation with chemotherapeutic efficacy was analyzed. Serum concentrations of PITG and Flt-1 were detected in control and MM patients before and after chemotherapy by ELISA and their correlation with the chemotherapeutic efficacy was analyzed.
  
  
  RESULTS
  The effective rate of three-months-thalidomide-based chemotherapy was 54.3% in MM patients. The expression levels of PIGF and Flt-1 in MM patients' bone marrow were obviously higher than those in controls. After chemotherapy, PIGF and Flt-1 expression levels significantly reduced and the decline level was positively correlated with curative effecacy(r=0.71). The serum concentrations of PIGF and Flt-1 in MM patients' bone marrow were obviously higher than those in control. After chemotherapy, serum concentrations of PIGF and Flt-1 were significantly decreased and the decline level positively correlated with curative effecacy(r=0.87).
  
  
  CONCLUSIONS
  PIGF and FLT-1 are highly expressed in patients with multiple myeloma, and their expression levels positively correlates with curative effecacy of thalidomide-based chemotherapy.
authors.affiliation: Department of Hematology, Yongchuan Hospital Affiliated to Chongqing Medical University,Chongqing 402160, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Xiao
authors.affiliation: Department of Hematology, Yongchuan Hospital Affiliated to Chongqing Medical University,Chongqing 402160, China. E-mail：lilimiu2014@126.com.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Miao
mesh_terms: D001853:Bone Marrow; D006801:Humans; D008565:Membrane Proteins; D009101:Multiple Myeloma; D013792:Thalidomide; D040281:Vascular Endothelial Growth Factor Receptor-1
chemical_list: D008565:Membrane Proteins; C098069:PIGF protein, human; D013792:Thalidomide; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1